Treatment with the anti-IgE monoclonal antibody omalizumab in women with asthma undergoing fertility treatment: a proof-of-concept study-The PRO-ART study protocol

Casper Tidemandsen, Elisabeth Juul Gade, Charlotte Suppli Ulrik, Henriette Svarre Nielsen, Birgitte Sophie Oxlund-Mariegaard, Karsten Kristiansen, Nina La Cour Freiesleben, Bugge Nøhr, Hanne Udengaard, Vibeke Backer, Casper Tidemandsen, Elisabeth Juul Gade, Charlotte Suppli Ulrik, Henriette Svarre Nielsen, Birgitte Sophie Oxlund-Mariegaard, Karsten Kristiansen, Nina La Cour Freiesleben, Bugge Nøhr, Hanne Udengaard, Vibeke Backer

Abstract

Introduction: Asthma is associated with prolonged time to pregnancy and a higher need for fertility treatment. However, the mechanism underlying this association remains incompletely understood. Previous research points to asthma-driven systemic inflammation also affecting the reproductive organs and thereby fertility. The aim of this study was to determine if treatment with omalizumab prior to fertility treatment will increase pregnancy rate among women with asthma by decreasing the systemic asthma-related inflammation and, by that, to provide insight into the underlying mechanisms.

Methods and analysis: This is an ongoing prospective multicentre randomised controlled trial planned to enrol 180 women with asthma recruited from fertility clinics in Denmark. The patients are randomised 1:1 to either omalizumab or placebo. The primary endpoint is the difference in pregnancy rate confirmed with ultrasound at gestational week 7 of pregnancy. The secondary endpoints are change in sputum and blood eosinophil cell count, change in biomarkers, change in microbiota, together with rate of pregnancy loss, frequency of malformations, pre-eclampsia, preterm birth, birth weight, small for gestational age and perinatal death between groups.

Ethics and dissemination: The methods used in this study are of low risk, but if successful, our findings will have a large impact on a large group of patients as infertility and asthma are the most common chronic diseases among the young population. The study has been approved by the Ethics Committee-Danish national research ethics committee (H-18016605) and the Danish Medicines Agency (EudraCT no: 2018-001137-41) and the Danish Data Protection Agency (journal number: VD-2018486 and I-Suite number 6745). The test results will be published regardless of whether they are positive, negative or inconclusive. Publication in international peer-reviewed scientific journals is planned.

Trial registration number: NCT03727971.

Keywords: asthma; reproductive medicine; respiratory medicine (see thoracic medicine); subfertility.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Prevalence of chronic disease among young adults. Figure adapted from ‘Nielsen et al.
Figure 2
Figure 2
Flowchart of patients through the study.

References

    1. pp. Becker AB, Abrams EM. Asthma guidelines: the global initiative for asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol 2017;17:99–103. 10.1097/ACI.0000000000000346
    1. Gade EJ, Thomsen SF, Lindenberg S, et al. . Fertility outcomes in asthma: a clinical study of 245 women with unexplained infertility. Eur Respir J 2016;47:1144–51. 10.1183/13993003.01389-2015
    1. Gade EJ, Thomsen SF, Lindenberg S, et al. . Asthma affects time to pregnancy and fertility: a register-based twin study. Eur Respir J 2014;43:1077–85. 10.1183/09031936.00148713
    1. Grzeskowiak LE, Smithers LG, Grieger JA, et al. . Asthma treatment impacts time to pregnancy: evidence from the International scope study. Eur Respir J 2018;51:1702035. 10.1183/13993003.02035-2017
    1. Johnston S, Said J. Perinatal complications associated with maternal asthma during pregnancy. Obstet Med 2012;5:14–18. 10.1258/om.2011.110062
    1. Martel M-J, Rey Évelyne, Beauchesne M-F, et al. . Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005;330:230–3. 10.1136/bmj.38313.624352.8F
    1. Baghlaf H, Spence AR, Czuzoj-Shulman N, et al. . Pregnancy outcomes among women with asthma. J Matern Fetal Neonatal Med 2019;32:1325–31. 10.1080/14767058.2017.1404982
    1. Ali Z, Nilas L, Ulrik CS. Low risk of adverse obstetrical and perinatal outcome in pregnancies complicated by asthma: a case control study. Respir Med 2016;120:124–30. 10.1016/j.rmed.2016.10.004
    1. Vejen Hansen A, Ali Z, Malchau SS, et al. . Fertility treatment among women with asthma: a case-control study of 3689 women with live births. Eur Respir J 2019;53:1–3. 10.1183/13993003.00597-2018
    1. Sverrild A, Kiilerich P, Brejnrod A, et al. . Eosinophilic airway inflammation in asthmatic patients is associated with an altered airway microbiome. J Allergy Clin Immunol 2017;140:407–17. 10.1016/j.jaci.2016.10.046
    1. Schoenmakers S, Steegers-Theunissen R, Faas M. The matter of the reproductive microbiome. Obstet Med 2019;12:107–15. 10.1177/1753495X18775899
    1. Gade EJ, Thomsen SF, Lindenberg S, et al. . Lower values of VEGF in endometrial secretion are a possible cause of subfertility in non-atopic asthmatic patients. J Asthma 2015;52:336–42. 10.3109/02770903.2014.966915
    1. Evans PW, Wheeler T, Anthony FW, et al. . A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy. Hum Reprod 1998;13:1057–62. 10.1093/humrep/13.4.1057
    1. Seo WS, Jee BC, Moon SY. Expression of endometrial protein markers in infertile women and the association with subsequent in vitro fertilization outcome. Fertil Steril 2011;95:2707–10. 10.1016/j.fertnstert.2011.01.009
    1. Wang X, Zhao J, Qin L. Vegf-C mediated enhancement of lymphatic drainage reduces intestinal inflammation by regulating IL-9/IL-17 balance and improving gut microbiota in experimental chronic colitis. Am J Transl Res 2017;9:4772–84.
    1. Kuruvilla ME, Lee FEH, Lee GB, et al. . Endotypes, and mechanisms of disease. Clinical Reviews in Allergy and Immunology 2019;56:219–33.
    1. Bousquet J, Siergiejko Z, Świebocka E, et al. . Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011;66:671–8. 10.1111/j.1398-9995.2010.02522.x
    1. Beck LA, Marcotte GV, MacGlashan D, et al. . Omalizumab-induced reductions in mast cell FCE psilon RI expression and function. J Allergy Clin Immunol 2004;114:527–30. 10.1016/j.jaci.2004.06.032
    1. Saini SS, MacGlashan DW, Sterbinsky SA, et al. . Down-Regulation of human basophil IgE and Fc epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999;162:5624–30.
    1. Macglashan DW, Saini SS. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin Immunol 2013;132:906–11. 10.1016/j.jaci.2013.04.056
    1. Sue-Chu M, Brannan JD, Anderson SD, et al. . Airway hyperresponsiveness to methacholine, adenosine 5-monophosphate, mannitol, eucapnic voluntary hyperpnoea and field exercise challenge in elite cross-country skiers. Br J Sports Med 2010;44:827–32. 10.1136/bjsm.2009.071043
    1. Kharitonov SA, Walker L, Barnes PJ. Repeatability of standardised nasal nitric oxide measurements in healthy and asthmatic adults and children. Respir Med 2005;99:1105–14. 10.1016/j.rmed.2005.02.019
    1. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982;1:121–9. 10.1002/sim.4780010204
    1. Feng CH, Miller MD, Simon RA. The United allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy 2012;26:187–90. 10.2500/ajra.2012.26.3762
    1. Holt PG, Sly PD. Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. Chest 2011;139:1165–71. 10.1378/chest.10-2397
    1. Andersen A-M, Nielsen HS. Fertilitet og sundhed,” in Fosterlivet: Farefuldt og fantastiske fremtidsudsigter 2012:59–82.
    1. Namazy JA, Blais L, Andrews EB, et al. . Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J Allergy Clin Immunol 2020;145:528–36. 10.1016/j.jaci.2019.05.019
    1. Kupryś-Lipińska I, Tworek D, Kuna P. Omalizumab in pregnant women treated due to severe asthma: two of good outcomes of pregnancies. Pdia 2014;2:104–7. 10.5114/pdia.2014.40975
    1. Ensina LF, Cusato-Ensina AP, Camelo-Nunes IC, et al. . Omalizumab as third-line therapy for urticaria during pregnancy. J Investig Allergol Clin Immunol 2017;27:326–7. 10.18176/jiaci.0179
    1. Malara G, Sciarrone C. Chronic spontaneous urticaria treated with omalizumab: report of two cases. J Dermatolog Treat 2018;29:3–5. 10.1080/09546634.2018.1551608
    1. Nielsen HS, Schmidt L, Nyboe Andersen A, et al. . Forebyggelse AF nedsat frugtbarhed. København: Vidensråd for forebyggelse, 2016: s.23.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever